37.55
-0.76 (-1.98%)
| Penutupan Terdahulu | 38.31 |
| Buka | 37.36 |
| Jumlah Dagangan | 172,946 |
| Purata Dagangan (3B) | 529,214 |
| Modal Pasaran | 764,855,936 |
| Harga / Jualan (P/S) | 92.99 |
| Harga / Buku (P/B) | 1.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Operasi (TTM) | -856.97% |
| EPS Cair (TTM) | -10.21 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,349.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.31% |
| Nisbah Semasa (MRQ) | 10.77 |
| Aliran Tunai Operasi (OCF TTM) | -131.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -69.94 M |
| Pulangan Atas Aset (ROA TTM) | -43.81% |
| Pulangan Atas Ekuiti (ROE TTM) | -70.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Praxis Precision Medicines, Inc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.75 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.46% |
| % Dimiliki oleh Institusi | 110.91% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 105.00 (HC Wainwright & Co., 179.63%) | Beli |
| Median | 80.00 (113.05%) | |
| Rendah | 28.00 (Wedbush, -25.43%) | Jual |
| Purata | 75.17 (100.19%) | |
| Jumlah | 5 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 36.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 07 May 2025 | 80.00 (113.05%) | Beli | 38.09 |
| Needham | 05 May 2025 | 80.00 (113.05%) | Beli | 38.96 |
| 08 Apr 2025 | 85.00 (126.36%) | Beli | 28.60 | |
| Wedbush | 05 May 2025 | 28.00 (-25.43%) | Jual | 38.96 |
| HC Wainwright & Co. | 01 May 2025 | 105.00 (179.63%) | Beli | 38.06 |
| 03 Mar 2025 | 105.00 (179.63%) | Beli | 33.55 | |
| Baird | 03 Mar 2025 | 73.00 (94.41%) | Beli | 33.55 |
| Truist Securities | 03 Mar 2025 | 85.00 (126.36%) | Beli | 33.55 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |